Paul Baverel

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

Paul Baverel, Vincent F. S. Dubois, Chao Yu Jin et al. · Clinical Pharmacology & Therapeutics · 2017 · 151 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point

Emma C.Y. Hilton, Paul Baverel, Ashley Woodcock et al. · Journal of Allergy and Clinical Immunology · 2013 · 87 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma

Yanan Zheng, Rajesh Narwal, ChaoYu Jin et al. · Clinical Pharmacology & Therapeutics · 2017 · 57 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

Padmanee Sharma, Joohyuk Sohn, Sang Joon Shin et al. · Clinical Cancer Research · 2019 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing

Paul Baverel, Meena Jain, Iwona Stelmach et al. · British Journal of Clinical Pharmacology · 2015 · 29 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17